Department of Molecular Biology, Princeton University, Princeton, New Jersey 08544, USA.
Nationwide Children's Hospital, Columbus, Ohio 43205, USA.
Cold Spring Harb Perspect Med. 2020 May 1;10(5):a036970. doi: 10.1101/cshperspect.a036970.
Hepatitis C virus (HCV) is an important and underreported infectious disease, causing chronic infection in ∼71 million people worldwide. The limited host range of HCV, which robustly infects only humans and chimpanzees, has made studying this virus in vivo challenging and hampered the development of a desperately needed vaccine. The restrictions and ethical concerns surrounding biomedical research in chimpanzees has made the search for an animal model all the more important. In this review, we discuss different approaches that are being pursued toward creating small animal models for HCV infection. Although efforts to use a nonhuman primate species besides chimpanzees have proven challenging, important advances have been achieved in a variety of humanized mouse models. However, such models still fall short of the overarching goal to have an immunocompetent, inheritably susceptible in vivo platform in which the immunopathology of HCV could be studied and putative vaccines development. Alternatives to overcome this include virus adaptation, such as murine-tropic HCV strains, or the use of related hepaciviruses, of which many have been recently identified. Of the latter, the rodent/rat hepacivirus from species-1 (RHV-rn1) holds promise as a surrogate virus in fully immunocompetent rats that can inform our understanding of the interaction between the immune response and viral outcomes (i.e., clearance vs. persistence). However, further characterization of these animal models is necessary before their use for gaining new insights into the immunopathogenesis of HCV and for conceptualizing HCV vaccines.
丙型肝炎病毒 (HCV) 是一种重要且报告不足的传染病,在全球范围内导致约 7100 万人慢性感染。HCV 的宿主范围有限,仅能强有力地感染人类和黑猩猩,这使得在体内研究这种病毒具有挑战性,并阻碍了急需的疫苗的开发。围绕黑猩猩生物医学研究的限制和道德问题使得寻找动物模型变得更加重要。在这篇综述中,我们讨论了用于创建 HCV 感染的小动物模型的不同方法。尽管使用非人类灵长类动物(除黑猩猩外)的尝试具有挑战性,但在各种人源化小鼠模型中已经取得了重要进展。然而,这些模型仍然没有达到一个全面的目标,即拥有一个具有免疫功能、可遗传易感性的体内平台,在此平台中可以研究 HCV 的免疫病理学并开发潜在的疫苗。克服这一问题的替代方法包括病毒适应,例如嗜鼠型 HCV 株,或使用相关的肝病毒,最近已经鉴定出许多种。在后者中,1 型种的啮齿动物/大鼠肝病毒(RHV-rn1)作为可在完全免疫功能正常的大鼠中使用的替代病毒具有很大的应用潜力,它可以帮助我们理解免疫反应与病毒结果(即清除与持续存在)之间的相互作用。然而,在将这些动物模型用于深入了解 HCV 的免疫发病机制和构思 HCV 疫苗之前,需要对其进行进一步的特征描述。